Michael Milyavsky
Tel Aviv University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michael Milyavsky.
International Journal of Cancer | 2017
Shahar Biechonski; Dana Gourevich; Melanie Rall; Nasma Aqaqe; Muhammad Yassin; Adi Zipin-Roitman; Luba Trakhtenbrot; Leonid Olender; Yael Raz; Ariel J. Jaffa; Dan Grisaru; Lisa Wiesmüller; David Elad; Michael Milyavsky
Quercetin (Que) is an abundant flavonoid in the human diet and high‐concentration food supplement with reported pro‐ and anti‐carcinogenic activities. Topoisomerase II (TopoII) inhibition and subsequent DNA damage induction by Que was implicated in the mixed lineage leukemia gene (MLL) rearrangements that can induce infant and adult leukemias. This notion raised concerns regarding possible genotoxicities of Que in hematopoietic stem and progenitor cells (HSPCs). However, molecular targets mediating Que effects on DNA repair relevant to MLL translocations have not been defined. In this study we describe novel and potentially genotoxic Que activities in suppressing non‐homologous end joining and homologous recombination pathways downstream of MLL cleavage. Using pharmacological dissection of DNA‐PK, ATM and PI3K signalling we defined PI3K inhibition by Que with a concomitant decrease in the abundance of key DNA repair genes to be responsible for DNA repair inhibition. Evidence for the downstream TopoII‐independent mutagenic potential of Que was obtained by documenting further increased frequencies of MLL rearrangements in human HSPCs concomitantly treated with Etoposide and Que versus single treatments. Importantly, by engaging a tissue engineered placental barrier, we have established the extent of Que transplacental transfer and hence provided the evidence for Que reaching fetal HSPCs. Thus, Que exhibits genotoxic effects in human HSPCs via different mechanisms when applied continuously and at high concentrations. In light of the demonstrated Que transfer to the fetal compartment our findings are key to understanding the mechanisms underlying infant leukemia and provide molecular markers for the development of safety values.
Scientific Reports | 2018
Shahar Biechonski; Leonid Olender; Adi Zipin-Roitman; Muhammad Yassin; Nasma Aqaqe; Victoria Marcu-Malina; Melanie Rall-Scharpf; Magan Trottier; M. Stephen Meyn; Lisa Wiesmüller; Yael Raz; Dan Grisaru; Arnon Nagler; Michael Milyavsky
Failure to precisely repair DNA damage in self-renewing Hematopoietic Stem and early Progenitor Cells (HSPCs) can disrupt normal hematopoiesis and promote leukemogenesis. Although HSPCs are widely considered a target of ionizing radiation (IR)-induced hematopoietic injury, definitive data regarding cell death, DNA repair, and genomic stability in these rare quiescent cells are scarce. We found that irradiated HSPCs, but not lineage-committed progenitors (CPs), undergo rapid ATM-dependent apoptosis, which is suppressed upon interaction with bone-marrow stroma cells. Using DNA repair reporters to quantify mutagenic Non-Homologous End Joining (NHEJ) processes, we found that HSPCs exhibit reduced NHEJ activities in comparison with CPs. HSPC-stroma interactions did not affect the NHEJ capacity of HSPCs, emphasizing its cell autonomous regulation. We noted diminished expression of multiple double strand break (DSB) repair transcripts along with more persistent 53BP1 foci in irradiated HSPCs in comparison with CPs, which can account for low NHEJ activity and its distinct control in HSPCs. Finally, we documented clonal chromosomal aberrations in 10% of IR-surviving HSPCs. Taken together, our results revealed potential mechanisms contributing to the inherent susceptibility of human HSPC to the cytotoxic and mutagenic effects of DNA damage.
Oncoscience | 2016
Michael Milyavsky; Boris Gole; Lisa Wiesmüller
[This corrects the article on p. 938 in vol. 2, PMID: 26909360.].
Mutation Research | 2017
Johanna Flach; Michael Milyavsky
Experimental Hematology | 2016
Shahar Biechonski; Adi Zipin-Roitman; Lisa Wiesmüller; Katia Beider; Arnon Nagler; Michael Milyavsky
Oncoscience | 2015
Michael Milyavsky; Boris Gole; Lisa Wiesmüller
The FASEB Journal | 2018
Galia Tiram; Shiran Ferber; Paula Ofek; Anat Eldar-Boock; Dikla Ben-Shushan; Eilam Yeini; Adva Krivitsky; Roni Blatt; Nava Almog; Jack Henkin; Orit Amsalem; Eylon Yavin; Gadi Cohen; Philip Lazarovici; Joo Sang Lee; Eytan Ruppin; Michael Milyavsky; Rachel Grossman; Zvi Ram; Marcelo Calderón; Rainer Haag; Ronit Satchi-Fainaro
Experimental Hematology | 2016
Nasma Aqaqe; Michael Milyavsky
Blood | 2016
Katia Beider; Valeria Voevoda; Hanna Bitner; Evgenia Rosenberg; Hila Magen; Olga Ostrovsky; Merav Leiba; Noya Shilo; Avichai Shimoni; Michael Milyavsky; Amnon Peled; Arnon Nagler
Experimental Hematology | 2014
Michael Milyavsky; Olga I Gan; Mark van Delft; Sean P. McDermott; Adi Zipin-Roitman; Alla Buzina; Troy Ketela; Liran Shlush; Stephanie Xie; Veronique Voisin; Jason Moffat; Mark D. Minden; John E. Dick